Form 4: Verrica CFO Boosts Stake with Stock & Warrants

Verrica Pharmaceuticals' Interim CFO, John J. Kirby, acquired 3,536 shares of common stock and 884 Series C Warrants, increasing his beneficial ownership.

Summary

• John J. Kirby, Interim CFO of Verrica Pharmaceuticals Inc. (VRCA), purchased 3,536 investment units on November 25, 2025.
• Each investment unit was priced at $4.2425 and consists of one share of common stock and a Series C warrant for one-fourth of a share of common stock.
• This transaction resulted in the acquisition of 3,536 shares of common stock and 884 Series C Warrants.
• Following the transaction, Mr. Kirby beneficially owns 8,962 shares of common stock and 884 Series C Warrants.
• The reported share numbers reflect a 1-for-10 reverse stock split effected by the Issuer on July 24, 2025.
• The Series C Warrants are immediately exercisable, have an exercise price of $6.315, and are set to expire on November 25, 2030.
• The exercise of Series C Warrants is subject to a beneficial ownership cap, preventing the reporting person from exceeding 9.99% of the outstanding common stock immediately after exercise.

Sentiment

Score: 8

Explanation: The insider purchase by the Interim CFO is a strong positive signal, indicating management's belief in the company's value and future prospects. The acquisition of both stock and warrants further reinforces this positive outlook.

Positives

• The purchase of common stock and warrants by the Interim CFO signals management's confidence in the company's future prospects and potential for stock appreciation.
• Insider buying can often be interpreted by investors as a positive indicator of the company's intrinsic value.

Related Party Transactions

• John J. Kirby, Interim CFO, purchased 3,536 investment units from Verrica Pharmaceuticals Inc., which included common stock and Series C Warrants.

Stakeholder Impact

• Shareholders may experience increased confidence in the company due to the insider purchase, potentially leading to positive sentiment and demand for the stock.

Key Dates

Recommendation

Insider buying, particularly by a key executive like the Interim CFO, is often considered a strong bullish signal. It suggests that management believes the company's stock is undervalued or expects significant positive developments, making it an attractive investment opportunity.

Keywords

VRCA, Verrica Pharmaceuticals, Insider Trading, Form 4, Stock Purchase, Warrants, CFO, Beneficial Ownership